Discovery of Clonixeril as a Sub-Femtomolar Modulator of the Human STING Receptor
Wayne Guida,Robert Sparks,William Lawless,Sarah Lawless,Mark Eschenfelder,Rainer Metcalf,Kenyon Daniel,Anna Kharitonova,Grace Binder,Jamie Nunziata,Sauradip Chaudhury,Christine Gambino,Michelle Wilde,Donna Trask,Linette Harding,Jaret Crews,Mansi Gopu,Emilia Dalamangus,Robert Green,Elizabeth Nompleggi,Paul Thompson,Niketa Patel,Rekha Patel,Guy Bradley,Wesley Brooks,Mildred Acevedo-Duncan,Alan Mullen,James Leahy,Timothy Tran,Kathy Yang
DOI: https://doi.org/10.26434/chemrxiv-2024-bxr73
2024-11-07
Abstract:Stimulator of interferon genes (STING) is a transmembrane endoplasmic reticulum (ER) resident protein involved in innate immunity. STING activation occurs by binding of cyclic guanosine-(2'→5')-monophosphate-adenosine-(3'→5')-monophosphate (2’,3’-cGAMP) to STING, which leads to downstream production of type 1 interferons (IFN-1). We generated molecular dynamics (MD) equilibrated agonist and antagonist models of human STING (hSTING) for computer based screening and now report the discovery of clonixeril (CXL) as the most potent non-nucleotide hSTING modulator discovered to date. We demonstrate in vitro and in cellulo that CXL has two modes of interaction with hSTING, one with an EC50 above 1 nM and the other with an EC50 in the 1 fM - 100 aM range (10-15 – 10-16 M). In cell based experiments, when CXL is titrated below 1 nM, it displays inverse dose dependent antagonistic behavior toward hSTING. We have substantiated that CXL displays this exceptionally strong inhibitory effect on hSTING mediated IFN 1 production using a THP 1 cell luciferase reporter for interferon regulatory factor 3 (IRF3). Further characterization of CXL was performed in HEK293 cells and by using biophysical and biochemical techniques.
Chemistry